0000914190-16-000832.txt : 20160912 0000914190-16-000832.hdr.sgml : 20160912 20160912172726 ACCESSION NUMBER: 0000914190-16-000832 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20160908 FILED AS OF DATE: 20160912 DATE AS OF CHANGE: 20160912 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BIO-TECHNE Corp CENTRAL INDEX KEY: 0000842023 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 411427402 STATE OF INCORPORATION: MN FISCAL YEAR END: 0630 BUSINESS ADDRESS: STREET 1: 614 MCKINLEY PL N E CITY: MINNEAPOLIS STATE: MN ZIP: 55413 BUSINESS PHONE: 6123798854 MAIL ADDRESS: STREET 1: 614 MCKINLEY PLACE NE CITY: MINNEAPOLIS STATE: MN ZIP: 55413 FORMER COMPANY: FORMER CONFORMED NAME: TECHNE CORP /MN/ DATE OF NAME CHANGE: 19920703 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Gould Kevin S CENTRAL INDEX KEY: 0001662638 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-17272 FILM NUMBER: 161881610 MAIL ADDRESS: STREET 1: 1155 VIA VERA CRUZ CITY: SAN MARCOS STATE: CA ZIP: 92078 4 1 edgar.xml PRIMARY DOCUMENT X0306 4 2016-09-08 0000842023 BIO-TECHNE Corp TECH 0001662638 Gould Kevin S 2948 WAUNETA STREET NEWBURY PARK CA 91320 0 1 0 0 SVP Clinical Controls Common Stock 2016-09-08 4 S 0 524 110.503 D 1667 D Stock Options (Right to Buy) 97.23 2022-07-09 Common Stock 50000 50000 D Stock Options (Right to Buy) 97.23 2022-07-09 Common Stock 15000 15000 D Stock Options (Right to Buy) 88.23 2023-01-04 Common Stock 10000 10000 D Stock Options (Right to Buy) 106.59 2023-08-18 Common Stock 17371 17371 D Stock Options (Right to Buy) 106.59 2023-08-18 Common Stock 13028 13028 D Restricted Stock Units Common Stock 2111 2111 D The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.4934 to $110.5402 inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation. or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Includes 833 shares of restricted stock units that vest on 7/9/17 and 834 shares of restricted stock units that vest on 7/9/18. 50,000 common stock options vest if certain performance goals are achieved for the 12 months ending 05/31/18. Vests as to 2,500 shares on each of 01/04/17, 01/04/18, 01/04/19 and 01/04/20. Vests 4,343 shares on each of 8/18/17, 8/18/18 and 8/18/19, and 4,342 shares on 8/18/20. Vests in full or in part on 8/18/19 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. /s/ Elizabeth M. Dunshee as Attorney-in-Fact for Kevin Gould pursuant to Power of Attorney previously filed. 2016-09-12 EX-24 2 gouldpoa.htm GOULD POWER OF ATTORNEY

POWER OF ATTORNEY



 The undersigned hereby constitutes and appoints Brenda S. Furlow,

James Hippel, Melodie R. Rose and Elizabeth M. Dunshee, or either of

them acting alone, the undersigned's true and lawful attorneys-in-fact

and agent with full power of substitution and resubstitution, for the

undersigned and in the undersigned's name, place and stead, in any and

all capacities, to sign any or all Forms 3, Forms 4 and Forms 5

relating to beneficial ownership of securities of Bio-Techne Corporation

(the "Issuer"), to file the same, with all exhibits thereto and other

documents in connection therewith, with the Securities and Exchange

Commission and to deliver a copy of the same to the Issuer, granting

unto said attorney-in-fact and agent full power and authority to do and

perform each and every act and thing requisite and necessary to be done

in and about the premises, as fully to all intents and purposes as the

undersigned might or could do in person, hereby ratifying and

confirming all said attorneys-in-fact and agent, or his substitute or

substitutes, may lawfully do or cause to be done by virtue thereof.

The undersigned acknowledges that the foregoing attorney-in-fact, in

serving in such capacity at the request of the undersigned, is not

assuming any of the undersigned's responsibilities to comply with

Section 16 of the Securities Exchange Act of 1934.



 This Power of Attorney shall remain in effect until such time as

the undersigned is no longer subject to the provisions of Section 16 of

the Securities Exchange Act of 1934 with respect to securities of the

Issuer.



 IN WITNESS WHEREOF, the undersigned has caused this Power of

Attorney to be executed as of this 1st day of January, 2016.



              /s/ Kevin S. Gould